References

1. DACOGEN^® (decitabine) for Injection Prescribing Information. Bloomington, MN: MGI PHARMA, INC.; May 2006.
2. Kantarjian HM, Issa JP, Saba H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-1803.
3. Data on file.
4. Malcovati, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision makind. J Clin Oncol. 2005;23:7594-7603.
5. Malcovati, Porta MG, Pascutto C, et al. The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome. Blood. 2005;106:233a-234a. Abstract 791.
6. NCCN^® Clinical Practice Guidelines in Oncology™: Myelodysplastic Syndromes (Version 1.2007). © 2006 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org Accessed [August 9, 2007]. To view the most recent and complete version of the guideline, go online to http://www.nccn.org.
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
8. Kuykendall JR. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Annals Pharmacather. 2005;39:1700-1709.
9. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96:3671-3674.
10. Rüter B, Wijermans PW, Lübbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-Aza-2`-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006; 106:1744-1750.
11. Kantarjian HM, O’Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007; 109:265-273.
12. Mufti G, List AF, Gore SD, et al. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 2003:176-99.
13. Heaney ML, Golde DW. Myelodysplasia. Engl J Med 1999; 340:1649-60.
14. Aplastic Anemia & MDS International Foundation, Inc. Myelodysplastic Syndromes: Basic Explanations. Annapolis, MD; 2005:1-19.
15. Kouides PA, Bennett JM. Understanding Myelodysplastic Syndromes: A Patient Handbook. Myelodysplastic Syndromes Foundation, second edition, revised 2001. http://www.mds-foundation.org/patientinfo.htm.
16. Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87:1324-41.
17. Oki Y, Issa JP. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol 2007; 86:306-314.
18. National Cancer Institute Web site, Dictionary of Cancer Terms, http://www.nci.nih.gov/dictionary/.
19. MedlinePlus Web site, Medical Dictionary, http://www.nlm.nih.gov/medlineplus/mplusdictionary.html
20. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998 Apr 15;91(8):2985-90.

IMPORTANT SAFETY INFORMATION

DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using DACOGEN. Men should be advised not to father a child while receiving treatment with DACOGEN, and for 2 months afterwards. The most commonly occurring adverse reactions include neutropenia, thrombocytopenia, anemia, pyrexia, fatigue, nausea, cough, petechiae, constipation, diarrhea, and hyperglycemia.

DACOGEN is available by prescription only. Please see the important product information for DACOGEN for more information. This site does not contain everything that is known about DACOGEN. If you would like to know more, talk to your healthcare professional.

This web site contains information relating to various medical conditions and their treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professional. You should not use this information for diagnosing a health problem or disease. Individual responses to DACOGEN treatment may vary.

This site is intended for health care professionals in the United States only. The products discussed herein may have different product labeling in different countries.

All information collected in this Web site is held in strictest confidence and will only be used for purposes as specified and will not be sold or distributed to other parties.